• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CEO and President Slosman Marvin was granted 558,417 units of Restricted Stock Units, increasing direct ownership by 30% to 2,410,536 units (SEC Form 4)

    1/10/25 4:30:26 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Slosman Marvin

    (Last) (First) (Middle)
    C/O INSPIREMD, INC.
    6303 WATERFORD DISTRICT DRIVE, SUITE 215

    (Street)
    MIAMI FL 33126

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    InspireMD, Inc. [ NSPR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO and President
    3. Date of Earliest Transaction (Month/Day/Year)
    01/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Restricted Stock Units 01/07/2025 A 558,417(1) A $0 2,410,536 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Options to purchase common stock (right to buy) $2.71 01/07/2025 A 254,985 (2) 01/07/2035 Common Stock 254,985 $0 937,796 D
    Explanation of Responses:
    1. These restricted stock units vest and become exercisable in three equal annual installments, with 1/3 vesting on each of January 07, 2026, January 7, 2027 and January 7, 2028, subject to the Reporting Person's continued service.
    2. The options vest and become exercisable in three equal installments, with 1/3 vesting on each of January 07, 2026, January 7, 2027 and January 7, 2028, subject to the Reporting Person's continued service.
    Remarks:
    Exhibit 24.1: Power of Attorney
    /s/ Craig Shore, Attorney-in-Fact for Marvin Slosman 01/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NSPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • InspireMD Reports First Quarter 2025 Financial Results

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

      5/9/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

      MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time / 10:15AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the "News & Events" section of the company's website at: https://www.inspiremd.com/en/events/ About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by pro

      4/30/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce First Quarter 2025 Financial Results

      MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

      4/25/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Tommasoli Andrea was granted 232,616 shares, increasing direct ownership by 47% to 727,694 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:33 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Director Berman Michael was granted 32,491 shares, increasing direct ownership by 14% to 264,533 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:18 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • CEO and President Slosman Marvin was granted 558,417 units of Restricted Stock Units, increasing direct ownership by 30% to 2,410,536 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      1/10/25 4:30:26 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    See more

    $NSPR
    Financials

    Live finance-specific insights

    See more

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

      MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of Directors. Mr. Ward most recently served as Chief Executive Officer and President of Cardiovascular Systems, Inc. prior to its acquisition by Abbott (NYSE:ABT) in April 2023. Paul Stuka, Chairman of the Board of InspireMD, stated, "We are extremely fortunate to add Scott to what I consider to be a world-class Board of Directors. With his extensive operational experience and track record in the cardiovascular space, his

      11/25/24 4:05:00 PM ET
      $ABT
      $NSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

      TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that the Company has appointed principal investigators (PIs) for its upcoming C-GUARDIANS II clinical trial of the SwitchGuard™ Neuroprotection System (NPS). Patrick Geraghty, M.D., professor of surgery and radiology, section of vascular surgery at Washington University School of Medicine in St. Louis, MO, and Patrick Muck, M.D., program director and chief of vascular surgery at Good Samaritan Hospital in Cincinnati, OH, have enthusiastically agreed to act as lead PIs for the trial.

      2/12/24 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

      Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports inducement grant under NASDAQ listing rule 5635(c)(4) TEL AVIV, Israel and MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- InspireMD (NASDAQ:NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the appointment of medical technology executive Pete Ligotti as Executive Vice President and General Manager of North America. Mr. Ligotti brings more than 30 years of general management and commercial leadership experience to the InspireMD team. Marvin Slosman, Chief Executive Officer of InspireMD

      1/3/24 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Reports First Quarter 2025 Financial Results

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. Optimistic for an anticipated approval in the third quarter of 2025Advanced commercial infrastructure and operational readiness ahead of anticipated U.S. launchContinued enrollment with excellent pace in the CGUARD

      5/9/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD to Announce First Quarter 2025 Financial Results

      MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by

      4/25/25 9:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

      MIAMI, March 12, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights: Engaged with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent system in the U.S. ahead of an anticipated first half 2025 approvalAnnounced approval of and enrolled first patients in the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use du

      3/12/25 7:00:00 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by InspireMD Inc.

      SC 13G - InspireMD, Inc. (0001433607) (Subject)

      12/4/24 4:31:06 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      11/14/24 6:35:20 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

      SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

      10/28/24 4:02:11 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Roubin Gary S bought $126,540 worth of shares (50,000 units at $2.53), increasing direct ownership by 13% to 438,902 units (SEC Form 4)

      4 - InspireMD, Inc. (0001433607) (Issuer)

      12/4/23 4:15:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care

    $NSPR
    SEC Filings

    See more
    • InspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - InspireMD, Inc. (0001433607) (Filer)

      5/9/25 7:09:33 AM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by InspireMD Inc.

      10-Q - InspireMD, Inc. (0001433607) (Filer)

      5/8/25 4:05:21 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by InspireMD Inc.

      DEFA14A - InspireMD, Inc. (0001433607) (Filer)

      4/16/25 4:05:25 PM ET
      $NSPR
      Medical/Dental Instruments
      Health Care